PCV15 vs PCV13: Better Pneumococcal Protection?
- The V114 vaccine (Vaxneuvance), a 15-valent pneumococcal conjugate vaccine (PCV15) developed by Merck & Co., demonstrates improved immune response against serotypes 22F and 33F in infants.
- Invasive pneumococcal disease (IPD) poses a significant threat to infants and young children.
- The Food and Drug Governance (FDA) approved V114 in June 2022 for individuals aged 6 weeks and older, protecting against S.
Discover if the V114 vaccine provides superior protection against pneumococcal disease. This article by News Directory 3 dives into a new meta-analysis comparing the V114 vaccine (PCV15) to the PCV13 vaccine, revealing enhanced immunogenicity against serotypes 22F and 33F in infants, the primary_keyword. Learn how this research could reshape infant pneumococcal disease protection by addressing the rising cases caused by specific serotypes. The secondary_keyword,invasive pneumococcal disease (IPD),is a severe threat,causing hundreds of thousands of deaths in children worldwide each year. The study indicates the V114 vaccine’s safety profile is similar to PCV13, but with potentially better results. Delve into the comparative analysis of both vaccines and the responder rates for various serotypes. Discover what’s next in the fight against IPD.
V114 Vaccine Shows Promise in infant Pneumococcal Disease Protection
Updated May 30, 2025
The V114 vaccine (Vaxneuvance), a 15-valent pneumococcal conjugate vaccine (PCV15) developed by Merck & Co., demonstrates improved immune response against serotypes 22F and 33F in infants. A new meta-analysis published in Vaccine: X indicates its safety is similar to the existing 13-valent pneumococcal conjugate vaccine (PCV13).
Invasive pneumococcal disease (IPD) poses a significant threat to infants and young children. worldwide, Streptococcus pneumoniae (S. pneumoniae) infections, the primary cause of IPD, result in approximately 300,000 deaths annually in children younger than 5, according to the World Health Association. While PCVs like PCV13 have decreased IPD rates, concerns persist about increasing IPD cases caused by serotypes not included in these vaccines, particularly 22F and 33F.
The Food and Drug Governance (FDA) approved V114 in June 2022 for individuals aged 6 weeks and older, protecting against S. pneumoniae serotypes in PCV13, plus 22F and 33F. Studies suggest V114 elicits a stronger immune response to serotypes 22F and 33F compared to PCV13. researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the immunogenicity and safety of PCV15 versus PCV13 in infants.
The analysis included nine RCTs with a total of 9,970 infants: 6,030 in the V114 group and 3,040 in the PCV13 group.For most shared serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 18C, 19A, 19F, and 23F), a higher proportion of infants in the PCV13 group showed a positive immune response.However, serotype 3 showed a significantly higher seropositivity rate in the V114 group (RR: 1.71). Seropositivity rates for other shared serotypes, excluding 3 and 6B, were not statistically significant.
The V114 vaccine demonstrated responder rates above 96% for serotypes 22F and 33F,compared to 4.77% and 4.01% respectively, in the PCV13 group. Geometric mean concentrations were also higher for serotypes unique to V114 in the V114 group. Pooled analysis favored V114 for both serotypes.
Safety outcomes were similar between the two vaccines (RR: 1.00). While the overall incidence of adverse effects at the injection site was comparable,instances of erythema,swelling,or pain were more frequent in the V114 group.
“By assessing and understanding these vaccines’ efficacy and potential adverse effects, public health authorities can better determine which vaccine aligns with local epidemiological needs and ensures optimal coverage,” the study authors wrote. “Additionally, the data on possible adverse effects enables healthcare providers to anticipate and manage these reactions, perhaps reducing their impact and improving patient outcomes.”
What’s next
Further research and monitoring will help determine the long-term impact of V114 on the prevalence of IPD caused by serotypes 22F and 33F, informing future vaccination strategies.